Filip Josephson

2.2k total citations · 1 hit paper
30 papers, 1.5k citations indexed

About

Filip Josephson is a scholar working on Infectious Diseases, Virology and Epidemiology. According to data from OpenAlex, Filip Josephson has authored 30 papers receiving a total of 1.5k indexed citations (citations by other indexed papers that have themselves been cited), including 17 papers in Infectious Diseases, 10 papers in Virology and 6 papers in Epidemiology. Recurrent topics in Filip Josephson's work include HIV/AIDS drug development and treatment (12 papers), HIV/AIDS Research and Interventions (11 papers) and HIV Research and Treatment (10 papers). Filip Josephson is often cited by papers focused on HIV/AIDS drug development and treatment (12 papers), HIV/AIDS Research and Interventions (11 papers) and HIV Research and Treatment (10 papers). Filip Josephson collaborates with scholars based in Sweden, Netherlands and Germany. Filip Josephson's co-authors include Veronica Miller, Per Ljungman, Jens Lundgren, Raymund R. Razonable, Paul Griffiths, Hans H. Hirsch, Andreas Pikis, Garrett Nichols, Michael Boeckh and Anders Sönnerborg and has published in prestigious journals such as Clinical Infectious Diseases, Clinical Pharmacology & Therapeutics and AIDS.

In The Last Decade

Filip Josephson

29 papers receiving 1.4k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Definitions of Cytomegalovirus Infection and Disease in Transplant Patients for Use in Clinical Trials: Table 1.

2016 693 citations Filip Josephson, Veronica Miller et al. profile →

Peers

Countries citing papers authored by Filip Josephson

Since Specialization

Citations

This map shows the geographic impact of Filip Josephson's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Filip Josephson with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Filip Josephson more than expected).

Fields of papers citing papers by Filip Josephson

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Filip Josephson. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Filip Josephson. The network helps show where Filip Josephson may publish in the future.

Co-authorship network of co-authors of Filip Josephson

This figure shows the co-authorship network connecting the top 25 collaborators of Filip Josephson. A scholar is included among the top collaborators of Filip Josephson based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Filip Josephson. Filip Josephson is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	The European Medicines Agency review of entrectinib for the treatment of adult or paediatric patients with solid tumours who have a neurotrophic tyrosine receptor kinase gene fusions and adult patients with non-small-cell lung cancer harbouring ROS1 rearrangements 2021 ·ESMO Open ·Julio Delgado, (unknown), Daniela Melchiorri, Cristina Migali, Filip Josephson, Harald Enzmann, Francesco Pignatti	21
2	EMA Review of Acalabrutinib for the Treatment of Adult Patients with Chronic Lymphocytic Leukemia 2021 ·The Oncologist ·Julio Delgado, Filip Josephson, Jorge Camarero, (unknown), Lucía López‐Anglada, (unknown), Paula B. van Hennik, (unknown), Christian Gisselbrecht, Harald Enzmann, Francesco Pignatti	8
3	European Medicines Agency extension of indication to include the combination immunotherapy cancer drug treatment with nivolumab (Opdivo) and ipilimumab (Yervoy) for adults with intermediate/poor-risk advanced renal cell carcinoma 2020 ·ESMO Open ·(unknown), Jorge Camarero, Paula B. van Hennik, B. Bolstad, (unknown), (unknown), (unknown), Mats Ökvist, Filip Josephson, Brigitte Keller‐Stanislawski, Nikolaos Zafiropoulos, (unknown), Jonas Bergh, Silvy da Rocha Dias, Francesco Pignatti	5
4	EMA Recommendation for the Pediatric Indications of Plerixafor (Mozobil) to Enhance Mobilization of Hematopoietic Stem Cells for Collection and Subsequent Autologous Transplantation in Children with Lymphoma or Malignant Solid Tumors 2020 ·The Oncologist ·Dominik Karres, (unknown), Paula B. van Hennik, Sabine M. J. M. Straus, Filip Josephson, (unknown), (unknown), Carla Herberts, (unknown), Ralf Herold, (unknown), Francesco Pignatti	19
5	Combinations in the first-line treatment of patients with advanced/metastatic renal cell cancer: regulatory aspects 2020 ·ESMO Open ·Luca Moscetti, Paula B. van Hennik, B. Bolstad, Jorge Camarero, Filip Josephson, Daniela Melchiorri, (unknown), Jan Sjöberg, (unknown), Jan Mulder, Didier Meulendijks, (unknown), Nikolaos Zafiropoulos, Jonas Bergh, Harald Enzmann, Francesco Pignatti	1
6	Antiretroviral treatment for HIV infection: Swedish recommendations 2016 2016 ·Infectious Diseases ·Jaran Eriksen, Jan Albert, Anders Blaxhult, Christina Carlander, Leo Flamholc, Magnus Gisslén, Filip Josephson, (unknown), Lars Navér, Veronica Svedhem, Aylin Yilmaz, Anders Sönnerborg	18
7	Treatment of hepatitis C virus infection in adults and children: Updated Swedish consensus recommendations 2012 ·Scandinavian Journal of Infectious Diseases ·Martin Lagging, Ann‐Sofi Duberg, Rune Wejstål, Ola Weiland, Magnus Lindh, Soo Aleman, Filip Josephson, (unknown)	14
8	Novel clinical trial designs for the development of new antiretroviral agents 2012 ·AIDS ·Nina Mani, Jeffrey S. Murray, Roy M. Gulick, Filip Josephson, Veronica Miller, Peter Miele, Jur Strobos, Kimberly Struble	12
9	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2010 2011 ·Scandinavian Journal of Infectious Diseases ·Lars Navér, Jan Albert, Erik Belfrage, Leo Flamholc, Magnus Gisslén, Katarina Gyllensten, Filip Josephson, (unknown), Susanne Lindgrén, Karin Pettersson, Veronica Svedhem, Anders Sönnerborg, Katarina Westling, Aylin Yilmaz	13
10	Differential Effects of Efavirenz, Lopinavir/r, and Atazanavir/r on the Initial Viral Decay Rate in Treatment Naïve HIV-1–Infected Patients 2010 ·AIDS Research and Human Retroviruses ·Arvid Edén, Lars‐Magnus Andersson, (unknown), Leo Flamholc, Filip Josephson, Staffan Nilsson, Vidar Ormaasen, Veronica Svedhem, (unknown), Anders Sönnerborg, Petra Tunbäck, Magnus Gisslén	14
11	Drug–drug interactions in the treatment of HIV infection: focus on pharmacokinetic enhancement through CYP3A inhibition 2010 ·Journal of Internal Medicine ·Filip Josephson	50
12	The relation between treatment outcome and efavirenz, atazanavir or lopinavir exposure in the NORTHIV trial of treatment-naïve HIV-1 infected patients 2009 ·European Journal of Clinical Pharmacology ·Filip Josephson, (unknown), Leo Flamholc, Magnus Gisslén, Lars Hagberg, Vidar Ormaasen, Anders Sönnerborg, Jan Vesterbacka, Ylva Böttiger	16
13	Treatment of HIV infection: Swedish recommendations 2009 2009 ·Scandinavian Journal of Infectious Diseases ·Filip Josephson, Jan Albert, Leo Flamholc, Magnus Gisslén, (unknown), Lars Moberg, Lars Navér, Veronica Svedhem, Bo Svennerholm, Anders Sönnerborg	14
14	Treatment of hepatitis C virus infection: Updated Swedish Consensus recommendations 2009 ·Scandinavian Journal of Infectious Diseases ·Martin Lagging, Rune Wejstål, Ingrid Uhnoo, Barbro Gerdén, Björn Fischler, Styrbjörn Friman, Filip Josephson, Olle Karlström, Per Sangfelt, (unknown), Ola Weiland, (unknown), (unknown), (unknown)	22
15	CYP3A induction and inhibition by different antiretroviral regimens reflected by changes in plasma 4β-hydroxycholesterol levels 2008 ·European Journal of Clinical Pharmacology ·Filip Josephson, Leif Bertilsson, Ylva Böttiger, Leo Flamholc, Magnus Gisslén, Vidar Ormaasen, Anders Sönnerborg, Ulf Diczfalusy	54
16	Prophylaxis and treatment of HIV-1 infection in pregnancy: Swedish Recommendations 2007 2008 ·Scandinavian Journal of Infectious Diseases ·Lars Navér, Ann‐Britt Bohlin, Jan Albert, Leo Flamholc, Magnus Gisslén, Katarina Gyllensten, Filip Josephson, P Pehrson, Anders Sönnerborg, Katarina Westling, Susanne Lindgrén	5
17	Antiretroviral treatment of HIV infection: Swedish recommendations 2007 2007 ·Scandinavian Journal of Infectious Diseases ·Filip Josephson, Jan Albert, Leo Flamholc, Magnus Gisslén, (unknown), (unknown), Lars Navér, Eric Sandström, (unknown), Bo Svennerholm, Anders Sönnerborg	24
18	CYP3A5 Genotype has an Impact on the Metabolism of the HIV Protease Inhibitor Saquinavir 2007 ·Clinical Pharmacology & Therapeutics ·Filip Josephson, (unknown), Mohamed Janabi, Jane Sayi, Eleni Aklillu, Mary Jande, (unknown), Jürgen Burhenne, Ylva Böttiger, Lars L. Gustafsson, Walter E. Haefeli, Leif Bertilsson	48
19	Early Virologic Rebound in a Pilot Trial of Ritonavir-Boosted Atazanavir as Maintenance Monotherapy 2006 ·JAIDS Journal of Acquired Immune Deficiency Syndromes ·Olle Karlström, Filip Josephson, Anders Sönnerborg	51
20	Identification of a novel specific CYP2B6 allele in Africans causing impaired metabolism of the HIV drug efavirenz 2006 ·Pharmacogenetics and Genomics ·Jue Wang, Anders Sönnerborg, Anders Rane, Filip Josephson, Stefan Lundgren, Lars Ståhle, Magnus Ingelman‐Sundberg	146

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact